What's Going On With Vanda Pharma Stock Tuesday?
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) stock rose Tuesday following the FDA’s recent approval of Bysanti, a new oral treatment for bipolar I disorder and schizophrenia.
FDA Approves Bysanti, Boosting Vanda’s Portfolio
The FDA’s approval of Bysanti marks a pivotal moment for Vanda, as it is set to serve as a first-line therapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for schizophrenia in adults.
The company anticipates that Bysanti will be commercially available in the third quarter of 2026, with marketing exclusivity expected to be protected until 2044.
In clinical studies, Bysanti demonstrated bioequivalence to iloperidone, leveraging the established efficacy and safety data from the company’s previous drug, Fanapt, which saw net product sales of $33.2 million in the fourth quarter of 2025, reflecting a 25% increase year-over-year.
The company is also exploring Bysanti as a treatment for major depressive disorder, with ongoing clinical studies expected to conclude by the end of this year.
Technical Analysis
Currently, the stock is trading 5.5% below its 20-day simple moving average (SMA) and 10.2% below its 100-day SMA, indicating short-term weakness. Over the past 12 months, shares have increased by 25% and are currently positioned closer to their 52-week highs than lows.
The RSI is at 50.00, which is considered neutral territory, indicating that the stock is neither overbought nor oversold. Meanwhile, MACD is at 0.10, below its signal line at 0.15, indicating bearish pressure on the stock.
The combination of neutral RSI and bearish MACD suggests mixed momentum, indicating that traders should be cautious as the stock navigates its current technical setup.
- Key Resistance: $9.00
- Key Support: $7.50
VNDA Price Action: Vanda Pharmaceuticals shares were up 1.66% at $8.28 at the time of publication on Tuesday.
Photo by Tada Images via Shutterstock
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Global bond market sell-off intensifies: 10-year JGB yield hits 30-year high, 10-year US Treasury continues to fall, US stock index futures decline, oil rises, gold falls
US stock index futures declined, with Nasdaq futures extending their intraday loss to 0.6%, and S&P 500 futures falling by 0.4%. Japan's 10-year government bond yield surged 10 basis points on Thursday to 3.075%, reaching its highest level since August 1996. Brent crude rose 0.2%, while gold edged down by 0.2%, trading near $4,280 per ounce.
Altcoin FET Sits Inside a Massive Macro Uptrend, Experts Expect Bullish Comeback for FET
Morgan Stanley and Dell (DELL.US) COO have an in-depth discussion: "This time is different"—AI agents are not just another refresh cycle, but a TAM expansion; the probability of a $756 bull market scenario is rising
Morgan Stanley released a research report stating that after a one-on-one meeting with Jeff Clarke, Chief Operating Officer at Dell headquarters, they have gained a deeper understanding of their bullish thesis on Dell. However, they still maintain a "neutral" rating and a target price of $511.
US Stock IPO Preview: Rapid Revenue Expansion, How Will TTG International (TTG.US) Seek New Growth Opportunities in Cross-Border Logistics?
In the future, changes in the company's business scale, customer structure, and profitability will be key dimensions to observe its growth potential.
Crypto prices
More
